A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 11/30/-0001 |
| Start Date: | December 2012 |
| End Date: | May 2013 |
| Contact: | AstraZeneca Clinical Study Information |
| Email: | information.center@astrazeneca.com |
| Phone: | 800-236-9933 |
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Effect on Biomarkers of AZD3293 Including an Open-Label Food Effect Group in Healthy Male and Non-Fertile Female Volunteers
This is a single dose study in healthy male and female (of non-child bearing potential)
volunteers, to assess the safety, effects on the body, and blood and urine drug levels of
AZD3293. AZD3293 is being developed for the treatment of Alzheimer's Disease
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to
Assess the Safety, Tolerability, Pharmacokinetics and Effect on Biomarkers of AZD3293
Including an Open-Label Food Effect Group in Healthy Male and Non-Fertile Female Volunteers
Inclusion Criteria:
- Healthy male and female (of non-childbearing potential) subjects
- Body mass index (BMI) between 19 and 30 kg/m2 and weigh at least 50 kg and no more
than 100 kg
Exclusion Criteria:
- History or presence of psychiatric disease/condition, GI, renal, hepatic,
cardiovascular, psychiatric, or retinal diseases or disorders
- History of neurological disease, including seizures, recent memory impairment, or
clinically significant head injury
- History of use of antipsychotic drugs , or chronic use of antidepressant or
anxiolytic drugs
- Frequent use (more than 2 days per week during the last 12 weeks) of tobacco or other
nicotine products
We found this trial at
1
site
Click here to add this to my saved trials
